Posted 12/28/2023, 1:30:00 PM
Eli Lilly Soars on Obesity Drug Potential While Pfizer Struggles Post-COVID
- Eli Lilly's diabetes drug Mounjaro is seeing huge demand, and newly approved obesity drug Zepbound positions Lilly to benefit from growing weight loss market
- Eli Lilly stock has soared 56% in 2023 and trades at high valuation, but long-term growth prospects from new obesity drug Zepbound provide upside
- Avoid Pfizer stock due to struggling weight loss pipeline, declining COVID-19 catalyst, risks from pending Seagen acquisition
- Pfizer facing unpredictable free cash flow generation and potential dividend cuts
- Eli Lilly has broad portfolio beyond weight loss drugs in cancer, autoimmune diseases; over 1,000% long-term returns show ability to reward patient investors